Expanding Market Reach ImpriMed's successful deployment across more than 40 states and its recent expansion to a new facility in Palo Alto demonstrate a strong growth trajectory and increasing demand for its AI-driven cancer testing solutions in both veterinary and upcoming human healthcare markets.

Innovative Technology Adoption The company's integration of advanced AI, machine learning, and cloud-based tech stack highlights its commitment to cutting-edge drug response prediction, positioning it as a top-tier provider for institutions seeking sophisticated, personalized treatment solutions for oncology.

Strategic Industry Presence Participation in major industry events such as the American Society of Hematology Annual Meeting and inclusion in Mayo Clinic’s accelerator program provide valuable opportunities for form partnerships and expanding visibility among healthcare providers and research institutions.

Robust Funding and Revenue With over $24 million in funding and a revenue range of $25 million to $50 million, ImpriMed is financially well-positioned for growth, research investments, and scaling its personalized medicine offerings into broader markets, including human healthcare.

Market Opportunity in Pet and Human Healthcare ImpriMed’s success in veterinary cancer testing, combined with its plans to extend AI solutions to human oncology, presents a compelling sales opportunity to veterinary clinics, research hospitals, and biotech firms interested in innovative personalized treatment technologies.